Author | Van Weyenbergh, Johan Jozef Rosa Maria | |
Author | Wietzerbin, Juana | |
Author | Rouillard, Dany | |
Author | Barral Netto, Manoel | |
Author | Liblau, Roland | |
Access date | 2014-03-24T17:46:43Z | |
Available date | 2014-03-24T17:46:43Z | |
Document date | 2001 | |
Citation | VAN WEYENBERGH, J. et al. Treatment of multiple sclerosis patients with interferon-beta primes monocyte-derived macrophages for apoptotic cell death. Journal of Leukocyte Biology, v. 70, p.745-748, 2001. | pt_BR |
ISSN | 0741-5400 | |
URI | https://www.arca.fiocruz.br/handle/icict/7440 | |
Language | eng | pt_BR |
Publisher | Wiley-Liss | pt_BR |
Rights | open access | pt_BR |
Title | Treatment of multiple sclerosis patients with interferon-beta primes monocyte-derived macrophages for apoptotic cell death | pt_BR |
Type | Article | pt_BR |
Abstract | Although interferon (IFN)-b has shown
a significant clinical benefit in multiple sclerosis
(MS), its mechanism of action remains unclear. We
found that IFN-b treatment of patients with MS
resulted in a significant increase in apoptotic cell
death (measured by annexin V staining and nuclear
fragmentation) of monocyte-derived macrophages,
as compared with cells derived from patients before
treatment. Stimulation of the cells with IFN-b
in vitro resulted in an even further increase of
annexin V binding, as well as increased Fas (CD 95,
APO-1) expression. However, no increased Fas
expression, apoptotic monocytes, or monocytopenia
were observed upon in vivo treatment. This
indicates that IFN-b does not deliver a death signal
to monocytes but rather primes for subsequent macrophage
apoptosis upon activation or differentiation | pt_BR |
Affilliation | INSERM. Paris, França | pt_BR |
Affilliation | INSERM. Paris, França | pt_BR |
Affilliation | Institut Curie. Section de Recherche. Paris, França | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Centro de Pesquisa Gonçalo Moniz. Salvador, BA, Brasil | pt_BR |
Subject | In vivo | pt_BR |
Subject | CD 14 | pt_BR |
Subject | CD 64 | pt_BR |
Subject | CD 95 (Fas) | pt_BR |
DeCS | Apoptose | pt_BR |
DeCS | Fatores Imunológicos/uso terapêutico | pt_BR |
DeCS | Interferon beta/uso terapêutico | pt_BR |
DeCS | Macrófagos/patologia | pt_BR |
DeCS | Esclerose Múltipla/quimioterapia | pt_BR |
DeCS | Adulto | pt_BR |
DeCS | Anexina A5/metabolismo | pt_BR |
DeCS | Antígenos CD95/biossíntese | pt_BR |
DeCS | Antígenos CD95/genética | pt_BR |
DeCS | Apoptose/efeitos de drogas | pt_BR |
DeCS | Linhagem da Célula | pt_BR |
DeCS | Feminino | pt_BR |
DeCS | Humanos | pt_BR |
DeCS | Fatores Imunológicos/farmacologia | pt_BR |
DeCS | Interferon beta/farmacologia | pt_BR |
DeCS | Ativação de Macrófagos | pt_BR |
DeCS | Macrófagos/efeitos de drogas | pt_BR |
DeCS | Macrófagos/metabolismo | pt_BR |
DeCS | Masculino | pt_BR |
DeCS | Meia-Idade | pt_BR |
DeCS | Monócitos/efeitos de drogas | pt_BR |
DeCS | Monócitos/metabolismo | pt_BR |
DeCS | Esclerose Múltipla/imunologia | pt_BR |
DeCS | Esclerose Múltipla/patologia | pt_BR |